May 23, 2025

New Inhaled Treprostinil Option Approved

Yutrepia represents an additional therapeutic option within the prostacyclin class for the management of PAH and PH-ILD.

Conexiant

May 23, 2025

JAK Inhibitors Prove Best for COVID

A global analysis finds JAK inhibitors significantly reduce COVID-19 deaths and ventilation needs in hospitalized patients, outperforming other therapies.

Reuters

May 23, 2025

Can Herbs Be Used for the Treatment of Obesity-Linked Thyroiditis?

A new study found that five traditional herbs may influence obesity-linked Hashimoto’s thyroiditis through a process called efferocytosis, with quercetin emerging as a key compound involved in regulating immune activity.

Conexiant

May 22, 2025

Extensive-Stage SCLC: Lurbinectedin and Atezolizumab

Results from the global phase III IMforte trial found that maintenance therapy with a combination of the alkylating agent lurbinectedin and the PD-L1 inhibitor atezolizumab improved survival in some p...

The ASCO Post

May 22, 2025

New AAP Guidelines Refresh Atopic Dermatitis Care

Applying topicals 2 to 3 times per week to previously affected areas—even when the skin appears clear—can reduce flare frequency and improve quality of life.

Conexiant

May 21, 2025

Pregnancy Linked to Lower Long COVID Risk

New research analyzing over 72,000 pregnant COVID-19 patients reveals they face a significantly reduced risk of developing long-term symptoms compared to nonpregnant women, with key risk factors identified across both cohorts.

Conexiant

May 20, 2025

Cystic Fibrosis: New Evidence-Based Guidelines for Newborn Screening

New Cystic Fibrosis Foundation guidelines aim to improve consistency, equity, and accuracy in CF newborn screening nationwide

The Pathologist

May 20, 2025

No Trials, No Boosters, Says FDA

FDA to require new clinical trials for COVID booster approval in healthy Americans under 65, limiting fall availability to high-risk groups.

Reuters

May 20, 2025

ICU Sedation Economics: A $1 Difference

Study finds dexmedetomidine, clonidine, and propofol have comparable cost-effectiveness for critically ill patients on mechanical ventilation.

Conexiant